- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00277251
Alendronate Osteoporosis Study
April 10, 2017 updated by: Boston Children's Hospital
Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis
This trial will test the hypothesis that among 20 children and adolescents from Children's Hospital, Boston with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease and vasculitis, treatment of glucocorticoid-associated osteopenia and osteoporosis with 18 months of alendronate (FOSAMAX®, Merck & Co., Inc.) will result in greater improvement in the mean change of individual AP spine bone mineral density (BMD) (gm/cm2) determined by dual energy X-ray absorptiometry (DXA) than treatment with 18 months of standard of care therapy.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment
20
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 22 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must be diagnosed with either ulcerative colitis, Crohn's disease, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis, systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD) or vasculitis according to standard criteria where available, and according to treating physicians when not available.
- Subjects must have diminished AP lumbar spine (L1-L4) BMD by DXA (Hologic 4500) with a Z score ≤ -1.5 SD assessed within 8 weeks of the Baseline Visit.
- Subjects must have received daily, alternate day or weekly systemic glucocorticoid therapy for a minimum of six months total in their life-time.
- Subjects must be between the ages of 8 and 21 years, 11 months, at randomization. Although subjects younger than 8 years of age may be affected by osteoporosis, limited normative data prevents assignment of a BMD Z score for this group.
- Regarding subjects with child-bearing potential Females who have had at least one menstrual cycle must either be abstinent or must be using an effective method of birth control.
Exclusion Criteria:
- Current or recent (within 6 months) treatment with therapeutic doses of a bisphosphonate, calcitonin, human growth hormone, and heparin, all agents known to alter bone density
- A history of recent (within one year of screening) major upper gastrointestinal (GI) disease (above the jejunum), including, but not limited to, peptic ulcer, esophageal disease or active GI bleeding, or ever had surgery of the upper GI tract other than pyloroplasty. A history of abnormalities of the esophagus which delay esophageal emptying, such as stricture or achalasia
- Hyperthyroidism (suppressed thyroid stimulating hormone (TSH) and elevated free thyroxine (T4)), hyperparathyroidism (elevated parathyroid hormone (PTH)), malignancy, rickets, or osteomalacia (by history), all assessed within 8 weeks of the Baseline Visit.
- 25 (OH) vitamin D below 20 mg/L
- Planned or current pregnancy and/or breastfeeding
- Renal dysfunction defined as dependence on dialysis or a creatinine clearance < 35 ml/min, assessed within 4 weeks of the Baseline Visit. Creatinine clearance = [(height in cm x 0.55)/plasma creatinine] for all females and for males < 13 years old; [(height in cm x 0.70)/plasma creatinine] for males ³ 13 years old.
- Hepatic insufficiency defined as SGPT or SGOT greater than twice normal for age, assessed within 4 weeks of the Baseline Visit.
- Uncorrected hypocalcemia (ionized calcium>10% below age-adjusted range), assessed within 4 weeks of the Baseline Visit
- Known or suspected hypersensitivity to bisphosphonates
- Inability to follow instructions for dosing, including being unable to swallow the study medication with plain water first thing in the morning, stand or sit upright without any other food or beverage for at least 30 minutes following dosing and until their next meal
- Weight greater than 136 kg (300 lb), as the DXA is not reliable for subjects of this size
- Weight less than 17 kg (37 lb), assessed within 8 weeks of the Baseline Visit
- Permanent foreign body (prosthetic, surgical clips, permanent earring/umbilical ring) in region of results of the study
- Enrollment Procedures interest, or soft tissue calcinosis overlying the region of interest
- Inability to undergo dual energy X-ray absorptiometry or CT scan
- Developmental or cognitive delay which may interfere with cooperation and/or compliance with the procedures
- Subject expects to move out of the area during the study period, rendering follow-up per protocol impractical
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To test the hypothesis that among children and adolescents with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease and vasculitis, tr
|
Secondary Outcome Measures
Outcome Measure |
---|
Alternate outcome measures
|
Comparison of DXA and QCT
|
Predictors for response to alendronate
|
Growth velocity
|
Fracture assessment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Catherine Gordon, MD, Boston Children's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2003
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
June 1, 2006
Study Registration Dates
First Submitted
July 7, 2005
First Submitted That Met QC Criteria
January 13, 2006
First Posted (Estimate)
January 16, 2006
Study Record Updates
Last Update Posted (Actual)
April 11, 2017
Last Update Submitted That Met QC Criteria
April 10, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 04-12-187R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucocorticoid-Associated Osteopenia and Osteoporosis
-
University of Sao Paulo General HospitalCompletedOsteoporosis, Postmenopausal | Osteoporosis, OsteopeniaBrazil
-
Appalachian State UniversityNorth Carolina Agriculture & Technical State UniversityCompletedPostmenopausal Osteoporosis | Osteoporosis, OsteopeniaUnited States
-
Shanghai JMT-Bio Inc.Not yet recruitingGlucocorticoid Induced OsteoporosisChina
-
Chinese PLA General HospitalBeijing Jishuitan Hospital; Beijing Aerospace General HospitalUnknownOsteoporosis | Osteopenia, OsteoporosisChina
-
NestléInstitut National de la Recherche Agronomique; Centre de Recherche en Nutrition...CompletedOsteoporosis, OsteopeniaFrance
-
MeddocThe Research Council of Norway; TineRecruitingOsteopenia or OsteoporosisNorway
-
Aarhus University HospitalCompleted
-
Umm Al-Qura UniversityCompletedOsteopenia or OsteoporosisSaudi Arabia
-
Riphah International UniversityCompletedPostmenopausal Osteoporosis | Postmenopausal OsteopeniaPakistan
-
University of ValenciaCompletedPhysical Activity | Osteoporosis, Postmenopausal | Osteoporosis, Osteopenia
Clinical Trials on Alendronate
-
University of California, DavisNational Heart, Lung, and Blood Institute (NHLBI); Doris Duke Charitable FoundationNot yet recruitingOsteonecrosis | Avascular Necrosis | Sickle Cell Disease | Sickle Cell Anemia | Ischemic Necrosis
-
Aarhus University HospitalCompleted
-
Shanghai JMT-Bio Inc.Not yet recruitingGlucocorticoid Induced OsteoporosisChina
-
Göteborg UniversityCompletedOsteoporosis | Ankylosing SpondylitisSweden
-
National Institute of Diabetes and Digestive and...CompletedProstate Cancer | Osteoporosis | HypogonadismUnited States
-
National Taiwan University HospitalCompletedOsteoporosis | End-Stage Renal Disease
-
Chinese University of Hong KongRecruitingACL ReconstructionHong Kong
-
Aarhus University HospitalUniversity of AarhusCompleted
-
National Institute of Dental and Craniofacial Research...CompletedPolyostotic Fibrous DysplasiaUnited States
-
Ciudad Universitaria, SpainCompleted